Cargando…
Barriers and enablers to implementing antenatal magnesium sulphate for fetal neuroprotection guidelines: a study using the theoretical domains framework
BACKGROUND: Strong evidence supports administration of magnesium sulphate prior to birth at less than 30 weeks’ gestation to prevent very preterm babies dying or developing cerebral palsy. This study was undertaken as part of The WISH (Working to Improve Survival and Health for babies born very pret...
Autores principales: | Bain, Emily, Bubner, Tanya, Ashwood, Pat, Van Ryswyk, Emer, Simmonds, Lucy, Reid, Sally, Middleton, Philippa, Crowther, Caroline A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539663/ https://www.ncbi.nlm.nih.gov/pubmed/26283623 http://dx.doi.org/10.1186/s12884-015-0618-9 |
Ejemplares similares
-
Magnesium sulphate at 30 to 34 weeks’ gestational age: neuroprotection trial (MAGENTA) - study protocol
por: Crowther, Caroline A, et al.
Publicado: (2013) -
Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis
por: Crowther, Caroline A., et al.
Publicado: (2017) -
Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review
por: Bain, Emily S, et al.
Publicado: (2013) -
Antenatal magnesium sulphate administration for fetal neuroprotection: a French national survey
por: Chollat, Clément, et al.
Publicado: (2017) -
Antenatal magnesium sulphate and adverse neonatal outcomes: A
systematic review and meta-analysis
por: Shepherd, Emily, et al.
Publicado: (2019)